NEKTAR THERAPEUTICS — Director's Dealing 2023

Aug 18, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEKTAR THERAPEUTICS (NKTR)
CIK: 0000906709
Period of Report: 2023-08-16

Reporting Person: Zalevsky Jonathan (Chief R&D Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-08-16	Common Stock	S	9703	$0.78	Disposed	283685	Direct

Footnotes

F1: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person.

F2: This transaction was executed in multiple trades at prices ranging from $0.75 to $0.83. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer.